Inferring expressed genes by whole-genome sequencing of plasma DNAPeter Ulz, Michael R. Speicher, Gerhard Thallinger et al.|Nature Genetics|2016Cited by 463
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F. Singer, Michael Gnant, Yen Y. Tan et al.|Clinical Cancer Research|2017Cited by 61
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F. Singer, Michael Gnant, Georg Pfeiler et al.|European Journal of Cancer|2020Cited by 52
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter Dubsky, Martin Filipits, Ralf Kronenwett et al.|European Journal of Cancer|2020Cited by 52
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F. Singer, Georg Pfeiler et al.|British Journal of Cancer|2021Cited by 16